ActRIIB Variant Protein Ligand Selectivity and Half-Life Extension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for potent regulators of TGF-beta signaling to manage physiological changes in muscle, bone, and other tissues, particularly for treating conditions like cachexia and muscle wasting disorders, where existing solutions are inadequate.
Innovation Solution
A variant ActRIIB protein with specific amino acid sequences and modifications, including acidic amino acids, PEGylation, and fusion with IgG heavy chain domains, is developed to inhibit signaling by myostatin and GDF11, offering targeted regulation of TGF-beta pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If wild-type ActRIIB protein is used to inhibit TGF-beta signaling, then muscle mass increases, but off-target effects on other tissues occur
Solution Approach 1:
The patent applies local quality by creating ligand-selective variants of ActRIIB that are biased toward binding specific ligands (GDF8/GDF11) over other TGF-beta family members. Through targeted amino acid mutations in the ligand-binding domain, the receptor achieves selective affinity for muscle-specific ligands, thereby increasing muscle mass while minimizing off-target effects on other tissues that respond to different TGF-beta ligands.
Solution Approach 2:
The patent utilizes parameter changes by modifying the amino acid sequence of ActRIIB at specific positions (e.g., positions 64, 79, and other residues in the ligand-binding domain) to alter its ligand-binding preferences. These sequence parameters are optimized to enhance binding affinity for GDF8/GDF11 while reducing binding to activin and other ligands,从而实现 selective inhibition of TGF-beta signaling pathways.
2Strength
If soluble ActRIIB protein is administered to treat muscle wasting disorders, then muscle growth is promoted, but the protein may be rapidly cleared from the body
Solution Approach 1:
The patent applies merging by fusing the ActRIIB protein with an Fc domain from an IgG antibody. This fusion creates a heterologous protein complex where the Fc domain provides extended half-life characteristics through FcRn-mediated recycling and protection from proteolytic degradation. The resulting fusion protein maintains the ligand-binding activity of ActRIIB while gaining the prolonged circulation time and reduced clearance associated with Fc-domain fusion proteins.
3Reliability
If ActRIIB variants with high ligand-binding affinity are created, then signaling inhibition is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent applies segmentation by focusing mutations and optimizations specifically within the ligand-binding domain (extracellular domain) of ActRIIB, while maintaining the rest of the protein structure intact. By localizing changes to the critical ligand-contact regions and using modular approaches to protein engineering, the patent achieves enhanced signaling inhibition without requiring complete redesign of the entire protein, thereby simplifying manufacturing compared to creating entirely novel proteins.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a variant ActRIIB protein comprising an amino acid sequence that is at least 90% identical to amino acids 29-109 of SEQ ID NO:2, wherein the protein comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO: 2.